Both Merck & Co. and Halozyme are holding their ground in a freshly unveiled patent dispute surrounding the New Jersey pharma’s under-the-skin version of its blockbuster cancer drug Keytruda.

A new patent dispute is brewing between Halozyme Therapeutics (NASDAQ:HALO), a biotech focused on drug delivery technology, and Merck (NYSE:MRK) over an injectable version of the New Jersey-based ...

In October, Merck took up an option on the personalised RNA-based cancer vaccine with an upfront payment of $250 million as part of a collaboration first agreed in 2016 and expanded in 2018.

In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against the other best undervalued stocks. How Will Tariffs Affect the Market? On March 5th, BBC reported ...

Merck booked just under $600 million last year in alliance revenues from the pair, but its attention is now moving to new therapies including sotatercept, a TGF-beta-targeting PAH drug Merck ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Derived prices are not provided by exchanges. They are derived by market makers in CFD OTC market and hence prices may not be accurate and may differ from the actual market price, meaning prices ...

Veterinary Infectious Disease Diagnostics Market valued at USD 2.1 Bn in 2023, and is expected to reach USD 5.4 Bn in 2033, CAGR of 10.2% Lawrence John Prudour +91 91308 55334 ...

U.S. Stocks Have Worst Day of 2025 as Economic Fears Grow The S&P 500 index fell 2.7 percent a day after President Trump refused to rule out that his aggressive trade policies could cause a ...